Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 49.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,638 shares of the biopharmaceutical company’s stock after selling 209,800 shares during the period. Ultragenyx Pharmaceutical makes up approximately 0.4% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 22nd largest position. Blue Owl Capital Holdings LP’s holdings in Ultragenyx Pharmaceutical were worth $4,891,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in RARE. Aquatic Capital Management LLC increased its holdings in Ultragenyx Pharmaceutical by 79.1% in the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company’s stock valued at $5,759,000 after purchasing an additional 84,559 shares during the last quarter. Thornburg Investment Management Inc. acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $2,083,000. Aberdeen Group plc increased its holdings in Ultragenyx Pharmaceutical by 94.3% in the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock valued at $29,288,000 after purchasing an additional 472,600 shares during the last quarter. WCM Investment Management LLC increased its holdings in Ultragenyx Pharmaceutical by 36.9% in the 3rd quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company’s stock valued at $8,747,000 after purchasing an additional 77,640 shares during the last quarter. Finally, Rafferty Asset Management LLC increased its holdings in Ultragenyx Pharmaceutical by 93.0% in the 3rd quarter. Rafferty Asset Management LLC now owns 156,484 shares of the biopharmaceutical company’s stock valued at $4,707,000 after purchasing an additional 75,388 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on RARE shares. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Wells Fargo & Company lifted their target price on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Barclays dropped their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $59.88.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $23.39 on Monday. The company has a fifty day simple moving average of $23.22 and a two-hundred day simple moving average of $26.07. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -3.83 and a beta of 0.39. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The business had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The business’s revenue was down 2.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.57) EPS. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.62 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 10,029 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $228,661.20. Following the completion of the transaction, the insider owned 110,026 shares in the company, valued at $2,508,592.80. The trade was a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the transaction, the executive vice president owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 117,262 shares of company stock valued at $2,687,403. Corporate insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.